Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia
This was a phase 2 trial of all-trans retinoic acid plus arsenic trioxide with or without gemtuzumab ozogamicin in acute promyelocytic leukemia, in which patients who had a white blood cell count >10…